Adare Pharma Solutions, headquartered in the United States, is a leading provider in the pharmaceutical industry, specialising in advanced drug delivery systems and formulation development. Founded in 2014, the company has rapidly established itself as a key player in the market, with a focus on enhancing the bioavailability and stability of complex molecules. With operational facilities across North America and Europe, Adare Pharma Solutions offers a diverse range of services, including customised formulation development, manufacturing, and packaging solutions. Their unique expertise in oral and topical dosage forms sets them apart, enabling clients to bring innovative therapies to market efficiently. Recognised for their commitment to quality and innovation, Adare Pharma Solutions has achieved significant milestones, positioning themselves as a trusted partner for pharmaceutical companies seeking to optimise their product offerings.
How does Adare Pharma Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Adare Pharma Solutions's score of 17 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Adare Pharma Solutions, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). Without emissions data or reduction initiatives, it is unclear how Adare Pharma Solutions is addressing climate change within its operations. The absence of reported figures suggests a need for enhanced transparency and commitment to sustainability practices in line with industry standards.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adare Pharma Solutions has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
